IMO $MGNX shows better result. MGC018 =50% PSA reduction in 5/7 mCRPC patients included all 7 mCRPC patients enrolled in 4 dose escalation cohorts of 0.5 mg/kg to 3 mg/kg unlike $ARVN ARV-110 =50% PSA reduction in 2/8 patients dosed at 140mg only. No response for 280mg dose.
Also $ARVN ARV-110 has renal toxicity. No position in either, just following. Do your own DD.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.